CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0197 (clinicaltrials.gov NCT No: NCT01059630)
Title:AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BENDAMUSTINE COMPARED WITH BENDAMUSTINE + RO5072759 (GA101) IN PATIENTS WITH RITUXIMAB-REFRACTORY, INDOLENT NON-HODGKIN’S LYMPHOMA
Principal Investigator:Nathan Fowler
Treatment Agent:Bendamustine HCl; Ofatumumab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if GA101 (obinutuzumab) in
combination with bendamustine can help to control rituximab-refractory NHL
compared to bendamustine alone. The safety of this drug combination will also
studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase III
Treatment Agents:Bendamustine HCl
Ofatumumab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Genentech, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nathan Fowler
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults